Amla prevents fructose-induced hepatic steatosis in ovariectomized rats: Role of liver FXR and LXRα

Climacteric

Volumn 18, Issue 2, 2015, Pages 299-310

  Koshy, S M ^a   Bobby, Z ^a   Jacob, S E ^a   Ananthanarayanan, P H ^a   Sridhar, M G ^a   Paulose, D T ^b  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b INDIRA GANDHI MEDICAL COLLEGE   (India)

Author keywords

abca1; emblica officinalis; Fatty liver; Insig 2; LDL receptor; menopause; PPAR ; srebp1

Indexed keywords

ABC TRANSPORTER A1; AMYLASE; BILIRUBIN; EMBLICA OFFICINALIS EXTRACT; FARNESOID X RECEPTOR; FATTY ACID; FATTY ACID SYNTHASE; FRUCTOSE; HIGH DENSITY LIPOPROTEIN; INSULIN INDUCED GENE 2 REGULATORY PROTEIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; OXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTECTIVE AGENT; REGULATOR PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROYL COENZYME A DESATURASE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; ORPHAN NUCLEAR RECEPTOR; PLANT EXTRACT; SIGNAL PEPTIDE;

AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; DRUG LIVER LEVEL; DRUG MECHANISM; DYSLIPIDEMIA; EMBLICA OFFICINALIS; FATTY ACID OXIDATION; FATTY LIVER; FEMALE; FRUCTOSE INDUCED HEPATIC STEATOSIS; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOLIPEMIA; LIPID METABOLISM; LIPID OXIDATION; LIPOGENESIS; LIVER FUNCTION; LIVER WEIGHT; MENOPAUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; LIVER; METABOLISM; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; FATTY ACID SYNTHASES; FATTY LIVER; FEMALE; FRUCTOSE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MENOPAUSE; ORGAN SIZE; ORPHAN NUCLEAR RECEPTORS; OVARIECTOMY; PHYLLANTHUS EMBLICA; PLANT EXTRACTS; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84924699367     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.933408     Document Type: Article

References (61)

1. Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007 Oct; 86: 899-906
2. Macdonald I. Infl uence of fructose and glucose on serum lipid levels in men and pre-and postmenopausal women. Am J Clin Nutr 1966; 18: 369-72
3. Gotto AM Jr. Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease: the Louis F. Bishop Lecture. J Am Coll Cardiol 2005; 46: 1219-24
4. Lim J S, M ietus-Snyder M, V alente A, S chwarz J-M, L ustig R H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010; 7: 251-64
5. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-50
6. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010; 3: 121-37
7. Satapathy SK, Sanyal AJ. Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab 2010; 21: 668-75
8. Yokozawa T, Kim HY, Kim HJ, Okubo T, Chu D-C, Juneja LR. Amla (Emblica offi cinalis Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. Br J Nutr 2007; 97: 1187-95
9. Sabu MC, Kuttan R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol 2002; 81: 155-60
10. Asmawi M Z, K ankaanranta H, M oilanen E, V apaatalo H. Anti-infl ammatory activities of Emblica offi cinalis Gaertn leaf extracts. J Pharm Pharmacol 1993; 45: 581-4
11. Koshy SM, Bobby Z, Hariharan AP, Gopalakrishna SM. Amla (Emblica offi cinalis) extract is effective in preventing high fructose diet-induced insulin resistance and atherogenic dyslipidemic profi le in ovariectomized female albino rats. Menopause 2012; 19: 1146-55
12. Chawla A, R epa J J, E vans R M, M angelsdorf D J. N uclear receptors and lipid physiology: opening the X-fi les. Science 2001; 294: 1866-70
13. Mehdizade R, A nsar M M, S oltani B, Babaei P. Effects of aerobic exercise training on visceral fat and serum adiponectin concentration in ovariectomized rats. Climacteric 2010; 13: 171-8
14. Babaei P, Mehdizadeh R, Ansar MM, Damirchi A. Effects of ovariectomy and estrogen replacement therapy on visceral adipose tissue and serum adiponectin levels in rats. Menopause Int 2010; 16: 100-4
15. Brunt EM. Pathology of fatty liver disease. Modern Pathol 2007; 20: S40-8
16. Goldstein J L, D eBose-Boyd R A, B rown M S. P rotein sensors for membrane sterols. Cell 2006; 124: 35-46
17. Miyazaki M, D obrzyn A, M an W C, e t a l. S tearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and-independent mechanisms. J Biol Chem 2004; 279: 25164-71
18. Koo H-Y, Miyashita M, Cho BHS, Nakamura MT. Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochem Biophys Res Commun 2009; 390: 285-9
19. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31
20. Horton J D, S hah N A, W arrington J A, e t a l. C ombined analysis of oligonucleotide microarray data from transgenic and knockout mice identifi es direct SREBP target genes. PNAS 2003; 100: 12027-32
21. Ntambi J M, M iyazaki M. R ecent insights into stearoyl-CoA desaturase-1. Curr Opin Lipidol 2003; 14: 255-61
22. Zhao C, D ahlman-Wright K. L iver X receptor in cholesterol metabolism. J Endocrinol 2010; 204: 233-40
23. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29: 431-8
24. Desvergne B, W ahli W. P eroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88
25. Schwartz K, Lawn RM, Wade DP. ABC1 gene expression and ApoA-I-mediated cholesterol effl ux are regulated by LXR. Biochem Biophys Res Commun 2000; 274: 794-802
26. Kennedy MA, Venkateswaran A, Tarr PT, et al. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J Biol Chem 2001; 276: 39438-47
27. Calpe-Berdiel L, R otllan N, F ié vet C, R oig R, B lanco-Vaca F, Escol a-Gil JC. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8. J Lipid Res 2008; 49: 1904-11
28. Repa J J, B erge K E, P omajzl C, R ichardson J A, H obbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002; 277: 18793-800
29. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol effl ux and immune responses. Arteriosclerosis, Thrombosis Vasc Biol 2010; 30: 139-43
30. Yu L, Hammer RE, Li-Hawkins J, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA 2002; 99: 16237-42
31. Yu L, L i-Hawkins J, H ammer R E, e t a l. O verexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 2002; 110: 671-80
32. Yu L, Y ork J, v on Bergmann K, L utjohann D, C ohen J C, Hobbs HH. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem 2003; 278: 15565-70
33. Wang Y, R ogers P M, S u C, V arga G, S tayrook K R, Burris TP. Regulation of cholesterologenesis by the oxysterol receptor, LXRalph a. J Biol Chem 2008; 283: 26332-9
34. Miao B, Zondlo S, Gibbs S, Cromley D, et al. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res 2004; 45: 1410-7
35. Cao G, Beyer TP, Yang XP, et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002; 277: 39561-5
36. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99: 7604-9
37. Honzumi S, Shima A, Hiroshima A, Koieyama T, Terasaka N. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits. Biochim Biophys Acta 2011; 1811: 1136-45
38. Grefhorst A, Elzinga B M, Voshol PJ, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002; 277: 34182-90
39. Kalaany NY, Mangelsdorf DJ. LXRS AND FXR: The yin and yang of cholesterol and fat metabolism. Ann Rev Physiol 2006; 68: 159-91
40. Rader DJ. Liver X receptor and farnesoid X receptor as therapeutic targets. Am J Cardiol 2007; 100: n15-19
41. Lambert G, A mar M JA, Guo G, Brewer H B J r, G onzalez F J, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003; 278: 2563-70
42. Yu L, Gupta S, Xu F, et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem 2005; 280: 8742-7
43. Watanabe M, H outen S M, W ang L, et a l. B ile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-18
44. Bilz S, S amuel V, M orino K, S avage D, C hoi C S, S hulman G I. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am J Physiol Endocrinol Metab 2006; 290: E716-22
45. Anila L, Vijayalakshmi NR. Flavonoids from Emblica offi cinalis and Mangifera indica-effectiveness for dyslipidemia. J Ethnopharmacol 2002; 79: 81-7
46. Jo Y, Lee PCW, Sguigna PV, DeBose-Boyd RA. Sterol-induced degradation of HMG CoA reductase depends on interplay of two Insigs and two ubiquitin ligases, gp78 and Trc8. Proc Natl Acad Sci USA 2011; 108: 20503-8
47. Lehrke M, L ebherz C, M illington S C, et a l. D iet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. Cell Metab 2005; 1: 297-308
48. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996; 383: 728-31
49. Hu X, Li S, Wu J, Xia C, Lala DS. Liver X receptors interact with corepressors to regulate gene expression. Mol Endocrinol 2003; 17: 1019-26
50. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and infl ammatory signaling. J Clin Invest 2006; 116: 607-14
51. Joseph S B, L affi tte B A, P atel P H, et a l. D irect and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 2002; 277: 11019-25
52. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-91
53. Timmins JM, L ee J-Y, B oudyguina E, et al. T argeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 115: 1333-42 Wellington 54. C L, W alker E KY, S uarez A, e t a l. A BCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 2002; 82: 273-83
54. C L, W alker E KY, S uarez A, e t a l. A BCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 2002; 82: 273-83
55. Vaisman B L, L ambert G, A mar M, et a l. A BCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 2001; 108: 303-9
56. Singaraja RR, Van Eck M, Bissada N, e t al. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation 2006; 114: 1301-9
57. Abidi P, Z hou Y, J iang J-D, L iu J. E xtracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005; 25: 2170-6
58. Savkur RS, Bramlett KS, Michael LF, Burris TP. Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor. Biochem Biophys Res Commun 2005; 329: 391-6
59. Kim H Y, Okubo T, Juneja L R, Yokozawa T. The protective role of amla (Emblica offi cinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr 2010; 103: 502-12
60. Park S-H, K im J-L, L ee E-S, et a l. D ietary ellagic acid attenuates oxidized LDL uptake and stimulates cholesterol effl ux in murine macrophages. J Nutr 2011; 141: 1931-7
61. Yoshimura Y, Nishii S, Zaima N, Moriyama T, Kawamura Y. Ellagic acid improves hepatic steatosis and serum lipid composition through reduction of serum resistin levels and transcriptional activation of hepatic ppara in obese, diabetic KK-A(y) mice. Biochem Biophys Res Commun 2013; 434: 486-91